The report "Bioresorbable Polymers Market by Type (Polylactic acid (PLA), Polyglycolic acid (PGA), Polylactic-co-glycolic acid (PLGA), Polycaprolactone(PCL)), application (orthopedic devices, drug delivery), and Region - Global Forecast to 2027", is projected to reach USD 688 million by 2027, at a CAGR of 10.5% from USD 417 million in 2022.
Browse 247 market data Tables and 56 Figures spread through 225 Pages and in-depth TOC on "Bioresorbable Polymers Market by Type (Polylactic acid (PLA), Polyglycolic acid (PGA), Polylactic-co-glycolic acid (PLGA), Polycaprolactone(PCL)), application (orthopedic devices, drug delivery), and Region - Global Forecast to 2027"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/bioresorbable-polymer-market-235258717.html
Resorbable or bioresorbable polymers find application as medical implants in the body. Once the mission, such as supporting an organ, surgical sutures, or controlled drug release, is performed, the body absorbs these polymers. The growing demand for patient-friendly drugs, which do not cause ill health and are quickly resorbed inside the body, is increasing the demand for resorbable polymer. 20 to 50 million more people suffer from non-fatal injuries with many occurring disabilities requiring surgical intervention.
In terms of value, PLA continues to be the largest type segment in 2021. Orthopedic devices is the largest application segment of the bioresorbable polymers market. In terms of value, North America was the largest market for bioresorbable polymers in 2021. The threat of substitutes is moderate in the bioresorbable polymers market, as no other polymers can deliver the same performance characteristics as that of bioresorbable polymers. The threat of new entrants is low in the market, as this market is relatively capital-intensive and requires a skillful workforce.
“PGLA is estimated to be the fastest-growing type in the bioresorbable polymers market for the forecast period.”
PLGA is the fastest-growing type of bioresorbable polymers and is expected to register a CAGR of 11.05%, in terms of value, during the forecast period. The high growth rate of PLGA-based bioresorbable polymers is mainly due to favorable reimbursement options, increasing awareness about novel medical devices, and the implementation of favorable government initiatives. According to an NCBI study, chronic diseases affect around 50% of the US population annually. It also estimated that chronic diseases accounted for ~86% of all healthcare costs in the US.
“Drug delivery was the second major application for the bioresorbable polymers market in 2021 in the global market”
The bioresorbable polymers market size for drug delivery applications accounted for the second-largest share of global bioresorbable polymers, in terms of value, in 2021. Bioresorbable polymers are used in the making of implantable matrices for controlled drug release inside the body. As the elderly are more susceptible to chronic disorders and diseases than other age groups, growth in this population segment will serve to increase patient volumes and, in turn, drive the demand for drugs and delivery technologies.
“North America is estimated to be the largest region in bioresorbable polymers market in 2020.”
North America was the largest bioresorbable polymers market, in terms of value, in 2021. Globally, it has been leading the market in demand and product innovation in terms of quality and application development. The growing demand backs the growth of the bioresorbable polymers market in the region for these polymers in the medical industry. Intense competition among major players in the market has led to price stabilization in the past few years.
The key market players profiled in the report include Corbion N.V. (The Netherlands), Evonik Industries AG(Germany), Foster Corporation (US), KLS Martin Group (Germany), DSM Biomedical (US), Inc, Ashland Global Holdings Inc. (US), Zeus Industrial Products(US), Inc, Seqens Group (France), REVA Medical, LLC (US), Poly-Med Incorporated (US), Bezwada Biomedical, LLC (US), Nomisma Healthcare Pvt. Ltd. (India), BMG Incorporated (Japan), Polysciences, Inc. (US), Huizhou Foryou Medical Devices Co., Ltd. (China), Musashino Chemical Laboratory, Ltd. (Japan), and Henan Xinghan Biotechnology Co. Ltd.(China).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441